MedTrace Logo

Comparison Between 2 Techniques for Lumbar-ESPB

NCT07104097 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2026-05-12

No results posted yet for this study

Summary

Diffusion of local anesthetics after a lumbar ESPB within fascial planes towards nerve structures is a matter of debate.

The main objective of the study is to compare the incidence of sensory block between two techniques of needle placement (superficial or translaminar) during lumbar ESPB block.

Patients are treated with lumbar ESPB (randomized to superficial or translaminar), spinal anesthesia and multimodal analgesia.

The primary endpoint will be the incidence of numbness/reduced skin sensitivity to cold (ice test) in the area innervated by the lumbar plexus. Secondary outcomes are pain and analgesic's consumption, motor block, quality of recovery and discharge ability.

Conditions

  • Hip Surgery

Interventions

PROCEDURE

spinal anesthesia

spinal anesthesia at L3-L4 plain bupivacaine 0.5% 2.2 ml

PROCEDURE

superficial erector spinal plane block (ESPB)

Lidocaine 1% + ropivacaine 0.25% 30 ml with adrenaline 1:200.000 on top of L3 transverse process, between bone and erector spinae muscle

PROCEDURE

deep (inter laminar) erector spinal plane block (ESPB)

Lidocaine 1% + ropivacaine 0.25% 30 ml with adrenaline 1:200.000 between L3 and L4 transverse process, between erector spinae muscle and deep muscles

DRUG

Dexamethasone

8 mg iv preoperatively

DRUG

Ibuprofen 400 mg

preoperatively and postoperatively (every 8 hours)

DRUG

Paracetamol

1000 mg preoperatively and postoperatively (every 8 hours)

DRUG

Morphine

Patient Controlled Analgesia

Sponsors & Collaborators

  • Papa Giovanni XXIII Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-06
Primary Completion
2026-08-20
Completion
2026-08-20

Countries

  • Italy

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07104097 on ClinicalTrials.gov